Arthneeti

Jenburkt Pharmaceuticals Share Price & Earnings Call Analysis

₹893.95+3.21% today
Market cap
₹395 Cr
P/E
11.03
ROE
20.25%
PEG
0.74
Price to sales
2.33
Debt to equity
0.01
52W high / low
₹1,276 / ₹854
Sales growth (5Y)
9.08%
EBITDA margin
24.19%
Net profit margin
22.13%
Promoter holding
46.62%
Sales (last year)
₹169 Cr

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Jenburkt Pharma rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Jenburkt Pharma.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Jenburkt Pharma

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Jenburkt Pharma

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +35293836393341374136464345
Expenses +28222928292330283027323630
Operating Profit779710911911913714
OPM %21%24%24%20%25%29%28%24%26%25%29%17%32%
Other Income +1111112222220
Interest0000000000000
Depreciation1011111111111
Profit before tax8710810101310121014814
Tax %21%28%23%31%24%26%23%32%28%23%29%29%21%
Net Profit +6575871079810611
EPS in Rs14.3912.1716.5912.2417.8616.8121.7514.7519.3517.6523.0213.4424.58

Financials of Jenburkt Pharma

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +8594103115123119109124137142152169
Expenses +7077849198998997106109111125
Operating Profit151620242520202730334044
OPM %18%18%19%21%20%17%18%22%22%23%27%26%
Other Income +233334455576
Interest000001000000
Depreciation322212222233
Profit before tax141720252721223033354447
Tax %33%36%34%32%26%30%24%25%25%26%27%25%
Net Profit +101114172015162225263235
EPS in Rs20.7623.1929.0637.5043.1432.4035.9548.5955.7658.8772.6478.72
Dividend Payout %30%31%28%24%24%25%28%25%26%26%25%26%

Financials of Jenburkt Pharma

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital555555554444
Reserves29365057737594113118141167193
Borrowings +756073573042
Other Liabilities +211216161821171816191926
Total Liabilities61587677103104120143141164195226
Fixed Assets +121211101012111110101519
CWIP00001000114046
Investments0125547811172127
Other Assets +494564628788103123119136120133
Total Assets61587677103104120143141164195226

Financials of Jenburkt Pharma

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +98101613151991782827
Cash from Investing Activity +1-0-101-11-3-19-13-1-17-19
Cash from Financing Activity +1-51-18-2-11-1-6-21-7-8-9
Net Cash Flow1121-101-03-103-2
Free Cash Flow8510161111187156813
CFO/OP88%82%85%103%80%104%127%62%83%49%102%88%

Financials of Jenburkt Pharma

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days322332406855474545505053
Inventory Days10710912873991209211592103109154
Days Payable5444724466585683677510091
Cash Conversion Cycle858889691011178377707859115
Working Capital Days-11610253532171631363141
ROCE %42%40%39%42%37%26%24%26%27%26%27%27%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals